KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) Equity Ratio (2016 - 2026)

Bristol Myers Squibb has reported Equity Ratio over the past 18 years, most recently at 0.23 for Q1 2026.

  • Quarterly Equity Ratio rose 7245.55% to 0.23 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.23 through Mar 2026, up 7245.55% year-over-year, with the annual reading at 0.21 for FY2025, 27.41% up from the prior year.
  • Equity Ratio was 0.23 for Q1 2026 at Bristol Myers Squibb, up from 0.21 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.31 in Q3 2023 and troughed at 0.44 in Q1 2024.
  • The 5-year median for Equity Ratio is 0.0 (2024), against an average of 0.01.
  • Year-over-year, Equity Ratio plummeted 14346.95% in 2024 and then soared 7245.55% in 2026.
  • A 5-year view of Equity Ratio shows it stood at 0.01 in 2022, then decreased by 22.79% to 0.02 in 2023, then skyrocketed by 1091.18% to 0.16 in 2024, then grew by 27.41% to 0.21 in 2025, then increased by 13.11% to 0.23 in 2026.
  • Per Business Quant, the three most recent readings for BMY's Equity Ratio are 0.23 (Q1 2026), 0.21 (Q4 2025), and 0.19 (Q3 2025).